Lung Cancer
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
From the Journals
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
Latest News
National Mine Safety Group Issues Rule to Reduce Silica Exposure
Inhaling silica or quartz dust can lead to lung cancer, fibrosis, chronic bronchitis, or kidney disease.
From the Journals
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
Feature
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
Researchers examine links between mortality risk and health-related social needs in patients who had cancer.
From the Journals
Terminal Cancer: What Matters to Patients and Caregivers
Patients and caregivers are less aligned on decisions about cost containment than end-of-life goals.
Latest News
The DEA Plans to Reschedule Marijuana: What Happens Next?
Following 2023 FDA information that legitimized marijuana as a medical treatment, DEA moves to lower its scheduling.
Feature
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
From the Journals
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
Commentary
‘We Need to Rethink Our Options’: Lung Cancer Recurrence
“Suddenly, we have better tools to control systemic spread.”
Conference Coverage
Is Osimertinib Better Alone or With Chemotherapy in Non–Small Cell Lung Cancer?
Randomized trial of 557 patients compares taking osimertinib alone to osimertinib with pemetrexed plus cisplatin or carboplatin, followed by...